| |
September 26, 2023 | 1:00 PM ET Planning to commercialize a gene therapy product? Learn how you can maximize revenue potential and navigate the market’s unique challenges with Trinity Life Sciences. Ready to tackle the elephant? Register Now.
|
|
Today’s Big NewsAug 28, 2023 |
|
Understand how to navigate EU regulations to launch rare disease medicines in European markets. Download guide.
|
|
| By Annalee Armstrong This year's Fierce 15 features companies pushing the envelope not only in the lab, in the clinic or on the conference circuit. |
|
|
|
By Nick Paul Taylor The long-frozen biotech IPO waters may be thawing slightly—provided you’re one part of a rare breed of biotech. Shortly after RayzeBio filed to go public, Neumora Therapeutics, another well-financed, late-phase business, made its pitch for funding to study treatments for brain diseases including depression. |
By James Waldron Things are continuing to look up for Bayer’s Parkinson’s disease cell therapy, with the German pharma giant finally offering a deeper dive into phase 1 data that confirms the candidate hit its key endpoints. |
Sponsored by Novartis Global Biotech Cooperations With the rapid increase in cell and gene manufacturing, companies need support from experienced, reliable, and global, CDMOs with a deep and rich technology network. |
By Max Bayer BridgeBio is expanding on phase 3 data of its cardiovascular med acoramidis months after positive topline results sent the company's stock soaring. BridgeBio still expects to submit an approval application to the FDA before the end of the year. |
Sponsored by IPM.ai Using artificial intelligence to predict and uncover de-identified rare disease patients shortens the time to diagnosis, benefiting both patients and life science companies. |
By Nick Paul Taylor Dan Paterson has wasted no time signing off on his first deal as CEO of Verastem Oncology. One month into the job, Paterson has put together a financial package worth up to $625.5 million to bag options on three GenFleet Therapeutics programs targeting cancers driven by the RAS pathway. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Angus Liu The Federal Trade Commission has paused its challenge of the $27.8 billion merger between Amgen and Horizon Therapeutics to rethink whether it should settle the case. |
By Andrea Park TTFields failed to meet its primary endpoint in a trial testing the combination of TTFields and paclitaxel chemotherapy in patients with platinum-resistant tumors, a group that makes up about 20% of all ovarian cancer patients. |
By Fraiser Kansteiner Danaher Corporation is picking up all outstanding shares of Abcam for $24 apiece. Both companies’ boards unanimously approved the decision, Danaher and Abcam said Monday. The deal is expected to close in mid-2024. |
By Nick Paul Taylor Moderna has returned for a second set at the U.S. Open. One year after partnering with Billie Jean King for a brand awareness campaign, the mRNA specialist is kicking off a new push focused on another of the changemakers of tennis: the late Arthur Ashe. |
By Andrea Park Nominations are now open for this year’s list of the fiercest women in pharma, biotech and medtech. |
| WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| WhitepaperIn oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchLearn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WebinarDownload this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
| |
|
